Guide contents
Open in calculatorCompound briefing
Thymosin Alpha-1 (Tα1) is a 28-amino-acid peptide derived from prothymosin alpha, originally isolated from thymus tissue. It is one of the most studied immunomodulatory peptides, with clinical use in several countries for immune restoration, hepatitis, sepsis and as a vaccine adjuvant.
The research question
Thymosin Alpha-1 affects both innate and adaptive immune activity. T-cell maturation, dendritic-cell function and cytokine regulation are key study variables, especially where immune suppression and excessive inflammation need to be distinguished.
Mechanism & research themes
Modulates innate and adaptive immunity by promoting T-cell differentiation and maturation, enhancing dendritic-cell and natural-killer-cell activity, and normalising cytokine balance. Also upregulates toll-like receptor expression and supports Th1-polarised immune responses.
Enhanced T-cell maturation and Th1 immune polarisation
Improved dendritic-cell and natural-killer-cell activity
Adjuvant activity for vaccine and anti-infective research
Restored immune competence in age-related or stress-induced immunosenescence
Regulation of inflammatory cytokine balance
Extensive clinical safety data in approved indications outside the US
These are research themes reported across the literature, not established benefits or indications.
Evidence assessment
Human studies and regional clinical use provide a substantial safety and immunology literature. Efficacy varies by indication, and immune-marker changes do not guarantee better clinical outcomes.
What to look for
Controlled design, a defined preparation, clinically relevant endpoints and independent replication carry more weight than a single mechanism study.
What not to assume
A plausible pathway does not establish efficacy. Results across different routes, formulations and populations are not automatically interchangeable.
Protocol literature
Commonly referenced research protocols use 1.6mg subcutaneously twice weekly, or 1mg daily for short immune-support courses. Cycles typically run 4–12 weeks, with breaks between courses. Subcutaneous administration in the abdomen or thigh is standard.
Reported persistence
Plasma half-life approximately 2 hours; immunomodulatory effects persist for days through downstream cell signalling.
Calculator starting point
1.6 mg per reference dose
2 doses per week · 12-week cycle
2 mL default reconstitution volume
1.6 mg SC twice weekly; typical immune-support cycle 4–12 weeks.
Calculator defaults are editable mathematical reference values, not dosing advice. Verify all calculations independently.
Calculate Thymosin Alpha-1Laboratory handling
Reconstitution reference
Reconstitute a 5mg vial with 2–3mL bacteriostatic water for a 1.6–2.5mg/mL working concentration. Swirl gently.
Storage reference
Lyophilised: 2–8°C, stable 18–24 months. Reconstituted: 2–8°C, protect from light, use within 28 days.
Minimum documentation standard
- Record the lot identifier and review its matching analytical documentation.
- Use aseptic technique and record diluent, final volume and calculated concentration.
- Label preparation date, storage conditions and any light or freeze–thaw restrictions.
- Inspect before each use and investigate unexpected colour, clarity or particulate changes.
Limitations & safety
Mild injection-site reactions are the most common adverse event.
Autoimmune conditions require caution due to immune-potentiating effects.
Use as a standalone immune therapy should be guided by research context and monitoring.
Research use only
This field note is an educational literature summary, not medical advice or a recommendation for human use. Safety statements are limited by the quality and duration of the available evidence.
Continue reading